conferenceseries.com

Tentative Program

16th Euro Global Summit and Expo on

Vaccines & Vaccination

June 19-21, 2017 Paris, France

Theme: "Accelerating Next Generation Vaccines for Global Health"



For Available Speaker Slots

eurovaccines@conferenceseries.net

Conference Secretariat

Conference Series LLC 2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA

Tel: +1-888-843-8169, Fax: +1-650-618-1417, Ph: +1-650-268-9744, Toll free: +1-800-216-6499

Email: eurovaccines@conferenceseries.net; eurovaccines@vaccineconference.com

http://nanomaterials.conferenceseries.com/

Day 1

Morning Sessions	Reception/Registration	08.00-09.00	
		Time	General Session
	Least of 3 Keynote Talks	09.00-09.15	Inaugural Address
		09.15-09.45	Keynote 1
		09.45-10.15	Keynote 2
		10.15-10.45	Keynote 3
	Panel Discussions/Group Photo		
	Coffee/Tea Break 10.45-11.00 (Networking)		
Evening Sessions	11.00-12.40	5 Speakers (20 Mins Each)	
	Lunch Break 12.40-13.30		
	13.30-15.30	6 Speakers (20 Mins Each)	
	Coffee/Tea Break 15.30-15.45 (Networking)		
	15.45-17.25	5 Speakers (20 Mins Each)	

Day 2

Morning Sessions		Time	General Session
	Least of 3 Keynote Talks	09.10-09.40	Keynote 1
		09.40-10.10	Keynote 2
		10.10-10.40	Keynote 3
	Coffee/Tea Break 10.40-10.55 (Networking)		
		Session 1	**Session 2**
	10.55-12.35	5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
Evening Sessions	**Lunch Break 12.35-13.25**		
	13.25-15.05	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**
	Poster Sessions		
	Coffee/Tea Break 15.05-15.20 (Networking)		
	15.20-17.00	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**

Day 3

Morning Sessions		Time	Session 1	Session 2
	09.00-10.40		5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Coffee/Tea Break 10.40-10.55 (Networking)			
	10.55-12.35		5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Lunch Break 12.35-13.25			
Evening Sessions	13.25-15.05		5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
	Awards & Closing Ceremony			

NOTE: Program Schedule is subject to change with final allotment of the speaker slots

For more Details PS: http://vaccines.global-summit.com/europe/

eurovaccines@conferenceseries.net

Glimpses of Vaccines & Vaccination





















http://vaccines.global-summit.com/europe/


Exhibitor
C.T.L.


conferenceseries.com


conferenceseries.com
Exhibitor
C.T.L.


1
US


conferenceseries.com
search


Speaker Representations
Supporters
FDA


conferenceseries.com
Exhibitor
C.T.L.
Immunome Research


conferenceseries.com
C.T.L.


conferenceseries.com
Exhibitor
C.T.L.


conferenceseries.com
June 16-18, 2016 Rome, Italy
Supporters
inovio
Kansas State University
allied
QUINTILES
World Health Organization



conferenceseries.com


conferenceseries.com


conferenceseries.com


conferenceseries.com


Media


Media Par


conferenceseries.com


conferenceseries.com


Event Partners
Media Partn


a Partners


conferenceseries.com

TOURIST DESTINATIONS IN PARIS, FRANCE




Eiffel Tower




Louvre



Arc de Triomphe




Notre Dame de Paris



Sacre-Coeur



Jardin du Luxembourg



Musee d Orsay



Place de la Concorde

Major Scientific Sessions

- Human Vaccines-Infectious & Non Diseases
- Infectious Diseases
- Vaccine Research & Development
- Cancer Vaccines
- HIV Vaccines
- Vaccine Safety & Efficacy
- Vaccination for pregnant women
- Childhood Vaccines
- Vaccine Adjuvants & Delivery Technologies
- Immunization for Older Adults
- Vaccines against Viral & Bacterial Diseases
- DNA Vaccines
- HPV Vaccines
- Veterinary vaccines
- Tuberculosis Vaccines
- Mucosal Vaccines
- Vaccines against Vector-borne Diseases
- Human Preventive & Therapeutic Vaccines
- Plant-based Vaccines

Best Poster Award



- You will be given about 5-7 minutes to present your poster including questions and answers. Judges may pose questions during the evaluation of the poster
- Judges will even evaluate the student's enthusiasm towards their study, interest and knowledge in the area of their research
- The winners will be announced at the closing ceremony of the conference. The decision of the winner will be withdrawn if the winner/winners is/are not present at the time of announcement
- Apart from the judging time you may also be present at the poster to share your research with interested delegates



Young Researchers Forum

- Present your research through oral presentations
- Learn about career development and the latest research tools and technologies in your field
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research
- Develop a foundation for collaboration among young researchers
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe
- Interact and share ideas with both peers and mentors

General Queries
eurovaccines@conferenceseries.net

Conference Venue

Paris, France

Contact us
America: Conference Series LLC
Euro Vaccines 2017
2360 Corporate Circle., Suite 400 Henderson,
NV 89074-7722, USA
Phone: +1-888-843-8169, Fax: +1-650-618-1417,
Toll free: +1-800-216-6499
Email: eurovaccines@conferenceseries.net

Contact us
UK: Conference Series LLC
Euro Vaccines 2017
Heathrow Stockley Park Lakeside House
1 Furzeground Way, Heathrow
UB11 1BD, UK
Tel: +1-800-216-6499
Email: eurovaccines@conferenceseries.net

Contact us
Asia-Pacific: Conference Series LLC
Euro Vaccines 2017
Divyasree Building, Raidurg
6th Floor, North Block
Hyderabad 500032, INDIA
Tel: 040-33432309
Email: eurovaccines@vaccineconference.com

conferenceseries.com

Scientific Program

10th Euro Global Summit and Expo on

Vaccines & Vaccination

June 16-18, 2016 Rome, Italy



Hosting Organization: Conference Series LLC

2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA **Ph:** +1-702-508-5200 Ext: 8047, **Toll free:** +1-800-216-6499

e-mail: eurovaccines@insightconferences.com; eurovaccines@conferenceseries.net

Registrations

Appia

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

Title: Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, France

Networking & Refreshments Break

Title: VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study
Prakash Bhuyan, Inovio Pharmaceuticals, USA

Group Photo

Track 1: Cancer Vaccines
Track 2: Vaccine Products and Delivery Technologies
Track 3: Vaccine Research and Development
Track 4: Vaccines for Respiratory Infections
Track 5: HIV Vaccines
Track 6: Veterinary vaccines

Session Chair: **Timothy R Fouts,** Profectus Biosciences Inc., USA
Session Co-chair: **Qingsheng Li,** University of Nebraska-Lincoln, USA

Session Introduction

Title: Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada
Title: Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA
Title: TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France
Title: Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland
Title: Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break

Title: Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France
Title: Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand
Title: Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy
Title: Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria
Title: Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumlic-Courtade, Merck Life Science, France
Title: MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break

Title: Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland
Title: Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland
Title: Plant expression platforms for vaccine production
Kathleen Hefferon, Cornell University, USA

Title: What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

Title: Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco
Ennima Imane , University Mohammed V of Rabat, Morocco
Title: Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco
Title: Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2 June 17, 2016

Appia

Keynote Forum

Title: Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein
Andrew Lees, Fina Biosolutions LLC, USA

Title: Human vaccines and vaccination for non-infectious diseases
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Networking & Refreshments Break

Title: Challenges and dilemmas about vaccines against the herpesviruses : The case of EBV
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases
Track 8: Viral Vaccines
Track 9: Bacterial Vaccines
Track 10: Childhood Vaccines
Track 11: Hepatitis Vaccines
Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
Andrew Lees, Fina Biosolutions LLC, USA

Session Introduction

Title: Rapid development of an oral Zika virus vaccine
Sean N Tucker, Vaxart Inc., USA
Title: Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections
Timothy R Fouts, Profectus Bio-Sciences, USA
Title: Measles: Need for continued vaccination and novel vaccines post virus eradication
S Louise Cosby, Agri-Food and Biosciences Institute, UK
Title: Evaluation of genetic stability of transgenes in vaccine
Ali Azizi, Sanofi Pasteur, Canada
Title: Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break

Title: The key person influences flu vaccination among health workers: Perspective study of social network
Xiaoning Hao, China National Health Development Research Center, China
Title: Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier
Giovana Cappio Barazzone, Instituto Butantan, Brazil
Title: Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China
Title: Pneumococcal inactivated whole cell vaccine: Development of the production process
Viviane Maimoni Goncalves, Instituto Butantan, Brazil
Title: Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study
Xiaoning Hao, China National Health Development Research Center, China
Title: Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees' context and post campaign results
Randa Hamadeh, Ministry of Public Health, Lebanon

Networking & Refreshments Break

Title: Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA
Title: Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion

Breakout

Cassia Meeting Room

Workshop on

Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

Session Chairs: **Barbara Ensoli,** National AIDS Center-Istituto Superiore di Sanità, Ital
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

Title: Expanding the findings of RV144 to South Africa: P5 initiative
Glenda Gray, South African Medical Research Council, South Africa

Title: Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments Break

Title: Current strategies for HIV remission: The role of therapeutic vaccines
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

Title: Synthetic DNA vaccines for difficult mucosal viruses including HIV
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA

Title: Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine
Adan Rios, PhotoImmune Biotechnology Inc., USA

11:50-12:20 Discussion

Lunch Break

Session Chairs: **Marc H.V. Van Regenmortel,** Biotechnology School of the University of Strasbourg, France
Eric Sandstrom, Karolinska Institutet, Sweden

Title: HIV vaccine development: Is a moral wrong occurring?
Mike King, University of Otago, New Zealand

Title: Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

Title: HIV replication is suppressed by CD8+T- regulatory cells in elite controllers
Jean Marie Andrieu, Paris-Descartes University, France

Title: Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments Break

Title: Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design
Massimo Amicosante, University of Rome, Italy

Workshop Discussion

Poster Presentations

EVACC 01 **Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response**
Jae-Hwan Nam, Catholic University of Korea, South Korea

EVACC 02 **Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging**
Hyewon Youn, Seoul National University, South Korea

EVACC 03 **Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system**
Sun Shin Yi, Soonchunhyang University, South Korea

EVACC 04 **Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against *Fasciola gigantica* in mice**
Narin Changklungmoa, Burapha University, Thailand

EVACC 05 **Vaccine potentials of recombinant mature cathepsin L1H against *Fasciola gigantica* in mice**
Pornanan Kueakhai, Burapha University, Thailand

EVACC 06 **Characterization and vaccination of the cytosolic *Fasciola gigantica* superoxide dismutase**
Wipaphorn Jaikua, Mahidol University, Thailand

EVACC 07 **Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)**
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea

EVACC 08 **Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability**
Suna Gu, Chonbuk National University, Republic of Korea

EVACC 09 **In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species**
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3 June 18, 2016

Appia

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines

Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France
Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction

Title: Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring
Sonali Kochhar, Global Healthcare Consulting, India

Title: Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments Break

Title: Operational experience and lessons learned on influenza vaccination post authorization safety studies
Ombretta Palucci, Quintiles, Switzerland

Title: Post-marketing surveillance of BCG vaccination
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan

Title: Novel vaccine adjuvants for animal infectious diseases
Jishu Shi, Kansas State University, USA

Title: Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break

Title: Immunogenicity of VLP forming baculoviral DNA vaccine
Young Bong Kim, Konkuk University, Republic of Korea

Title: Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan

Title: Therapeutic vaccines for treatment of allergic and autoimmune diseases
Zhikang Peng, University of Manitoba, Canada

Title: Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony

Scientific Program

Day 1 **July 27, 2015**

Registrations

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Allan Cripps
Pro Vice Chancellor, Griffith University, Australia

Nikolai Petrovsky
President, Global Vaccines conferences, OMICS International,
Research Director, Vaxine, Australia

Coffee Break:

Track 1: Technologies for The Design, Discovery, Formulation and Administration of Vaccines
Track 2: Vaccines For Pregnant Women
Track 5: Recent Advances in Animal Vaccination
Track 6: Adjuvants for Human / Animal Vaccines
Track 9: Advancements in Vaccine Development

Session Chair: **Nikolai Petrovsky**, President, Global Vaccines conferences, OMICS International, Research Director, Vaxine, Australia

Session Introduction

Title: Rational vaccine design against complex pathogens in the OMICS era
Denise Doolan, QIMR Berghofer, Australia
Title: Development of a Passive RSV Vaccine for Infants as an Alternative to Maternal Vaccination
Filip Dubovsky, MedImmune/AstraZeneca, USA
Title: A dendritic cell-targetted vaccine loaded with a glyceraldehyde-3-phosphate dehydrogenase peptide confers wide protection to listeriosis in susceptible and resistant mice
Carmen Alvarez-Dominguez, Proteomics and Vaccines, Spain
Title: Development and assessment of multivalent recombinant vaccines for bovine respiration disease
Timothy J Mahony, The University of Queensland, Australia

Group Photo

Lunch Break & Networking:

Title: Advax-adjuvanted killed Japanese Encephalitis Virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory
Helle Bielefeldt-Ohmann, Australian Infectious Diseases Research Centre, Australia
Title: Achievements and challenges in post-exposure vaccine development
Yuzhang Wu, The Third Military Medical University, China
Title: Novel non-genetic approach to improve the tuberculosis vaccine BCG
Zakaria Hmama, University of British Columbia, Canada

Keynote Talk

Kenneth Beagley
Deputy director, The leader of the Infectious Disease Research Program
Institute of Health Biomedical Innovation (IHBI)
Queensland University of Technology, Australia

Title: Chikungunya Virus vaccines?
Andreas Suhrbier, QIMR Berghofer Medical Research Institute, Australia

Coffee Break:

Title: Kunjin replicon-based vaccine candidate against Ebola virus
Alexander Khromykh, Australian Infectious Diseases Research Centre, Australia
Title: Future prospect of mosquito salivary components as novel target for vector based vaccine against Dengue: Molecular characterization of immunomodulatory protein from salivary glands of *Aedes aegypti*
Kartika Senjarini, University of Jember Indonesia, Indonesia
Title: Using carriage surveillance to show direct and indirect effects of pneumococcal conjugate vaccine
Fiona Russell, The University of Melbourne, Australia

Panel Discussion

Day 2 July 28, 2015

Keynote Forum

Mohammed Alsharifi
Director, Chief Scientific Officer, Gamma Vaccines, Australia

Roy Hall
Professor of virology, The University of Queensland, Australia

Track 11: Protein Subunits- Vaccination
Track 12: Toxoid vaccines and its importance
Track 14: Vaccines Under Research and Development, Major Diseases
Track 15: Innovative Development of Vaccines
Track 16: Mucosal vaccines

Session Chairs: Kenneth Beagley, Queensland University of Technology, Australia
Roy Hall, Professor of virology, The University of Queensland, Australia

Session Introduction

Title: Recruitability and Retention: The Challenges of Vaccine Trial design
Suzanne L. Elliott, Q-Pharm, Australia

Coffee Break

Title: Gamma-ray Inactivated Vaccines: Concepts and Applications
Lew-Tabor, The University of Queensland, Australia
Title: Nasal vaccine using nanoparticles against toxoplasma gondii infection: A mechanistic study
Didier Betbeder, University of Lille, France
Title: Unique IL-4R antagonist and IL-13Rα2 adjuvanted pox viral vector-based HIV vaccines
Charani ranasinghe, Australian National University, Australia
Title: Antigen-displaying polyester particles manufactured by engineered bacteria
Bernd Rehm, Massey University, New Zealand

Lunch Break & Networking

Young Research Forum

Title: Towards the development of oral vaccine delivery systems for lipid core peptide-based vaccines using novel multi-layer engineered nanoliposomes against Group A *streptococcus*
Nirmal Marasini, The university of Queensland, Australia
Title: A Protective Immune Response Using Asymmetric Multi-Epitope Self-Adjuvanting lipopeptide Vaccine Model
Sharareh Eskandari, The University of Queensland, Australia
Title: Binding and immune modulation properties of mannosylated lipo-peptide vaccines
Bita Sedaghat, The University of Queensland, Australia
Title: Best practice for communicating pertussis booster vaccine recommendations to new mothers: A randomised-control trial
Elizabeth Helen Hayles, Division of Women's and Children's Health, Australia
Title: Liposomes as a Delivery Platform of Vaccines Against Group A *Streptoccocus*
Khairunnisa Abdul Ghaffar, University of Queensland, Australia

Video Session

Title: Capsular polysaccharide loaded chitosan nanoparticles for mucosal immunization via respiratory tract against *Klebsiella Pneumonia*
Mala Menon, Bombay College of Pharmacy, India

Panel Discussion

Poster Session & Coffee Break

P1 **Title: New adjuvant G3/DT induces protective T cell response with a split-virion influenza vaccine**
Jan Fohlman, Växjö and Uppsala University, Sweden

P2 **Title: Enhanced Immunogenicity of A Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Formulated with Advax Adjuvant**
Hiroko Toriniwa, Kitasato daiichi sankyo vaccine co., Ltd. Japan

P3 **Title: Lipid core peptide nanoparticles as effective delivery system to trigger humoral immune responses against Group A *streptococcus* (GAS)**
Saranya Chandrudu, University of Queensland, Australia

P4 **Title: Optimization of nuclear-localization in a Multicomponent Non-viral Gene Delivery System**
Wei Dai, University of Queensland, Australia

P5 **Title: Targeting antigenic site on RSV F protein associated with virus neutralization for vaccine design**
Noushin Jaberolansar, University of Queensland, Australia

P6 **Title: Peptide-based self-assembled nanovaccine system targeting Group A *Streptococcus* infection**
Guangzu Zhao, University of Queensland, Australia

B2B Meetings

Day 3 July 28, 2015

Keynote Forum

Istvan Toth
ARC Australian Professorial Fellow, Chair-Biological Chemistry
Professor of Pharmacy, Director of Pharmaceuticals TetraQ
Group Leader, IMB Division of Structural Biology,
The University of Queensland, Australia

Track 2: Developing Next-Gen Conjugate Vaccines
Track 17: Childhood vaccines
Track 18: Cancer vaccines
Track 20: Delivery Technologies
Track 21: Vaccines Business and Development

Session Chair: **Mohammed Alsharifi,** Director, Chief Scientific Officer, Gamma Vaccines, Australia

Session Introduction

Title: Vaccine Manufacturing and Clinical Trial Services for Diarrheal Disease Product Development
Rodolfo M. Alarcón, NIH, USA
Title: Anti-cancer telomerase vaccines: Are they entering the age of maturity?
Gilberto Filaci, Professor, University of Genoa, Italy

Coffee Break

Title: Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and USA
Simon John Potter, Principal, Spruson & Ferguson, Australia
Title: Silica nanocarriers for delivery of single dose – shelf stable nano vaccines
Neena Mitter, The University of Queensland, Australia
Title: Rotavirus vaccines: Development, implementation and impact
Julie E. Bines, University of Melbourne, Australia
Title: How promising is the development of a meningococcal semi-synthetic conjugate vaccine? - a case study
Manoj Kumar Chhikara, Hilleman Labs, India
Title: Non-targeted effects of childhood vaccines: Epidemiological evidence and emerging immunological mechanisms
Katie Flanagan, Monash University , Australia

Lunch Break

Title: Key steps in moving a vaccine from proof of concept in mice to human clinical trials
Mark Reid, Clinical Network Services (CNS) Pty Ltd, Australia
Title: Use of system biology to identify genes associated with enhanced immunogenicity to a skin patch (nanopatch) delivered vaccine
Germain J. P. Fernando, University of Queensland, Australia
Title: Immunisation using microspheres of poly glycidyl methacrylate functionalized with MSA-2 peptide to protect cattle from babesiosis
Manuel Rodriguez-Valle, QAAFI/Centre for Animal Science, Australia

Title: A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant-Induced Split Ratio of Influenza Virus
Veysel Kayser, The University of Sydney, Australia

Panel Discussion

Award Ceremony